Investor resources
Why Invest?
Investment Highlights
Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study successfully completed demonstrating strong safety and a 67% Complete Response (“CR”) rate for patients treated at the therapeutic dose.
In-progress pivotal Phase II NMIBC clinical study under since November 2020.
Patented light-activated Photo Dynamic Compounds ("PDCs") have been scientifically and preclinically researched for 18+ years to optimize their ability to destroy cancer, bacteria and viruses.
Over 10+ peer reviewed published research publications.
Primary: NMIBC
Secondary: Non-Small Cell Lung Cancer ("NSCLC") , GlioBlastoma Multiforme ("GBM"), Vaccine for various enveloped viruses.
Contact Information
Transfer Agent:
TMX Equity Transfer Services Inc.
100 Adelaide Streety West, Suite 301,
Toronto, Ontario
M5H 1S3, CANADA
Work: 416-361-0930
Website: www.tsxtrust.com
Auditor:
AGT Partners LLP
7675 Highway 27
Unit 23
Woodbridge, Ontario
L4L 4M5, CANADA
Work: 905-266-0287
Fax: 905-266-1349
Web: www.agtllp.com
Chief Financial Officer/Investor Relations
Kristina Hachey, CPA
Theralase Technologies Inc.
41 Hollinger Road,
Toronto, Ontario
M4B 3G4, CANADA
Work: 416-699-5373 ext. 224
Email: khachey@theralase.com
Website: theralase.com
Our Partners
As part of our continuing mission to design, develop, and manufacture cutting-edge laser technologies, Theralase® has partnered with individuals and groups at the following institutions and organizations.
